SAVES-IBD: Safety & Efficacy of Aspirin vs. Standard of Care for VTE Prophylaxis After IBD Surgery (SAVES-IBD)
Primary Purpose
Crohn Disease, Ulcerative Colitis, Venous Thromboembolism
Status
Not yet recruiting
Phase
Phase 3
Locations
United States
Study Type
Interventional
Intervention
Aspirin 81Mg Ec Tab
Standard of Care
Sponsored by
About this trial
This is an interventional prevention trial for Crohn Disease focused on measuring surgery, prophylaxis
Eligibility Criteria
Inclusion Criteria:
- Age > 18yrs
- Major abdominopelvic surgery with colon or rectal resection
- Preoperative diagnosis of Crohn's disease, ulcerative colitis, indeterminate colitis
- Elective surgery
- candidate for standard of care VTE prophylaxis
Exclusion Criteria:
- age < 100 yrs
- aspirin allergy
- loop ileostomy closure
- emergency surgery
- peptic ulcer disease
- cirrhosis
- bleeding or clotting disorder
- thrombocytopenia
- chronic renal insufficiency or failure
- severe anemia < 7 preoperatively
- need for therapeutic anticoagulation or anti-platelet agents post-operatively including aspirin, warfarin, heparin, clopidogrel, rivaroxaban, others
Sites / Locations
- Cleveland Clinic Main Campus
Arms of the Study
Arm 1
Arm 2
Arm Type
Active Comparator
Experimental
Arm Label
Standard of Care
Aspirin
Arm Description
standard VTE chemoprophylaxis
Aspirin VTE chemoprophylaxis
Outcomes
Primary Outcome Measures
VTE Rate
Secondary Outcome Measures
Composite of bleeding requiring transfusion or intervention
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT05104229
Brief Title
SAVES-IBD: Safety & Efficacy of Aspirin vs. Standard of Care for VTE Prophylaxis After IBD Surgery
Acronym
SAVES-IBD
Official Title
SAVES-IBD: Safety & Efficacy of Aspirin vs. Standard of Care for VTE Prophylaxis After Major Surgery for Inflammatory Bowel Disease - A Pragmatic Clinical Trial
Study Type
Interventional
2. Study Status
Record Verification Date
July 2022
Overall Recruitment Status
Not yet recruiting
Study Start Date
June 1, 2023 (Anticipated)
Primary Completion Date
May 31, 2024 (Anticipated)
Study Completion Date
January 1, 2025 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
The Cleveland Clinic
4. Oversight
Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
Aim to determine if aspirin 81 mg orally twice daily is effective and safe as an extended VTE chemoprophylaxis agent after major abdominal surgery for IBD patients. Study will perform an open label trial of aspirin for VTE prophylaxis compared standard of care.
Detailed Description
Patients with inflammatory bowel disease who undergo abdominopelvic intestinal surgery are at increased risk for developing venous thromboembolism, in the form of deep vein thrombosis, pulmonary embolism and mesenteric vein thrombosis for 90-days after surgery. Despite being high-risk, the standard of care is to provide mechanical and chemoprophylaxis (unfractionated heparin or low molecular weight heparin) only while they are hospitalized. There exists randomized data, in patients who have had surgery for abdominopelvic cancer, confirming the efficacy of extended post-discharge chemoprophylaxis with either unfractionated heparin or low molecular weight heparin for 28 days after surgery, but no such data exists for IBD. There has been a resistance to adopting this for IBD patients due to compliance and cost of the daily injections. However, recently, a large, multicenter, randomized trial in >3000 patients who underwent total hip or total knee replacement found that extended aspirin (81 mg) twice daily post-discharge was both equivalent and non-inferior to prophylaxis using full-strength anticoagulation with a factor Xa inhibitor. This is a prospective, multicenter, open label clinical trial to assess the safety and efficacy of post-operative venous thromboembolism (VTE) prophylaxis with aspirin 81 mg orally twice daily for 30-days after surgery for IBD compared with controls receiving standard of care.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Crohn Disease, Ulcerative Colitis, Venous Thromboembolism
Keywords
surgery, prophylaxis
7. Study Design
Primary Purpose
Prevention
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Model Description
Two-armed open-labeled clinical trial
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
1890 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Standard of Care
Arm Type
Active Comparator
Arm Description
standard VTE chemoprophylaxis
Arm Title
Aspirin
Arm Type
Experimental
Arm Description
Aspirin VTE chemoprophylaxis
Intervention Type
Drug
Intervention Name(s)
Aspirin 81Mg Ec Tab
Intervention Description
Aspirin 81Mg Ec Tab by mouth twice daily starting the day after surgery until hospital discharge, then for 30 days
Intervention Type
Drug
Intervention Name(s)
Standard of Care
Intervention Description
Standard of Care VTE prophylaxis
Primary Outcome Measure Information:
Title
VTE Rate
Time Frame
30-days after discharge from hospital following IBD surgery
Secondary Outcome Measure Information:
Title
Composite of bleeding requiring transfusion or intervention
Time Frame
30-days after discharge from hospital following IBD Surgery
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
100 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Age > 18yrs
Major abdominopelvic surgery with colon or rectal resection
Preoperative diagnosis of Crohn's disease, ulcerative colitis, indeterminate colitis
Elective surgery
candidate for standard of care VTE prophylaxis
Exclusion Criteria:
age < 100 yrs
aspirin allergy
loop ileostomy closure
emergency surgery
peptic ulcer disease
cirrhosis
bleeding or clotting disorder
thrombocytopenia
chronic renal insufficiency or failure
severe anemia < 7 preoperatively
need for therapeutic anticoagulation or anti-platelet agents post-operatively including aspirin, warfarin, heparin, clopidogrel, rivaroxaban, others
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Stefan D Holubar, MD, MS
Phone
2164447000
Email
holubas@ccf.org
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Stefan D Holubar, MD, MS
Organizational Affiliation
The Cleveland Clinic
Official's Role
Principal Investigator
Facility Information:
Facility Name
Cleveland Clinic Main Campus
City
Cleveland
State/Province
Ohio
ZIP/Postal Code
44195
Country
United States
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Stefan D Holubar, MD/MS
Phone
216-444-7000
Email
holubas@ccf.org
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
SAVES-IBD: Safety & Efficacy of Aspirin vs. Standard of Care for VTE Prophylaxis After IBD Surgery
We'll reach out to this number within 24 hrs